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Abstract
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Objetive: The regulations on the advertisement of medications aim to encourage and promote an improved
health care and the rational use of medications. The objective of this paper is to evaluate the influence of three
regulations on the advertisement of medications: the “Export act”, published in the United States in 1986; the
“WHO’s Criteria”, published in 1988, and the Resolution 102/2000 of the Collegiate Board of Directors of the
ANVISA (Agência Nacional de Vigilância Sanitária- Brazilian Sanitary Surveillance Agency), on the
advertisement of psychoactive medications.
Method: We collected advertisements that were published in Brazilian psychiatric journals before and after the
regulations were established. The contents of the advertisements were analyzed according to a program created
based on the regulation’s demands.
Results: In the 118 analyzed issues there were 199 different advertisements on 85 psychotropic drugs. We
observed that, regardless the studied medication, the information about restrictions of use, such as adverse drug
reactions, interactions, contraindications, warnings and precautions, does not appear very often, and when it
does, its print sizes were smaller than that of the information favoring the use, such as indication, presentation
and dosage. After the publication of the regulations, only 38.2% of the advertisements had all the essential
technical information, and 35.3% were irregular in some way.
Conclusion: The data suggest that there was very little influence of the regulations on the advertisement of
psychotropic drugs in Brazil. Consequently, other control measures are necessary in addition to the regulations.
Advertising. Legislation about drug. Legislation on medication. Psychotropic drugs.
Objetivo: Os regulamentos sobre propaganda de medicamentos visam apoiar e fomentar a melhoria da atenção
à saúde e o uso racional de medicamentos. O objetivo deste trabalho é avaliar a influência de três regulamentos
sobre propaganda de medicamentos: “Export act”, publicado em 1986 nos Estados Unidos; os “Critérios da
OMS”, em 1988 e a Resolução da Diretoria Colegiada n° 102 de 2000 da ANVISA (Agência Nacional de
Vigilância Sanitária), sobre os anúncios de medicamentos psicoativos.
Método: Foram coletados anúncios em periódicos de psiquiatria nacionais, publicados antes e após cada regu-
lamento. O conteúdo dos anúncios foi analisado de acordo com um roteiro de análise de conteúdo elaborado
segundo as exigências dos regulamentos.
Resultados: Dos 118 fascículos analisados, foram obtidos 199 anúncios diferentes de 85 medicamentos psicoati-
vos. Observou-se que, independentemente do regulamento estudado, as informações que restringem o uso, como
reações adversas ao medicamento (RAM), interações, contra-indicações, advertências e precauções estão presen-
tes em menor freqüência e num tamanho de letra menor do que as informações que favorecem o uso, como
indicação, apresentação e posologia. Depois de todos os atos publicados apenas 38,2% dos anúncios continham
todas as informações técnicas imprescindíveis, e 35,3% dos anúncios apresentavam alguma irregularidade.
Conclusão: Os dados sugerem que houve pouca influência dos regulamentos sobre os anúncios de medicamen-
tos psicoativos no Brasil, portanto, faz-se necessário adotar outras medidas de controle além de regulamentos.
Publicidade. Leis sobre medicamentos. Legislação. Publicidade de medicamentos. Psicotrópicos.
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Introduction
Non-ethical promotion of medications is a major problem in
most of the world, mainly in developing countries, what can
generate an irrational use, and promote overprescription, self-
medication and abuse.1
The main goal of regulations about drug advertisement is to
incentive the improvement of medical care by means of a ra-
tional use of medications,2 assuring that physicians do not pro-
vide negative consequences to their patients due to the infor-
mation contained in the advertisements.
With that aim, the US Congress by means of the EXPORT
ACT of 1986 obliged the American multinational companies to
provide, in the advertisements of their medications in other coun-
tries, the same information about indication and restriction of
use approved by the Food and Drug Administration (FDA).3
Up to then, medications in the US which had not been ap-
proved by the FDA were exported and commercialized in other
countries such as Brazil.4
In 1988, with the same goal, the World Health Organization
(WHO) adopted the ‘Ethical and scientific criteria for drug
advertisement’. This document aimed to regulate the publica-
tions about medications for medical professionals and the pub-
lic, as well as the distribution of free samples for the public,
pharmacovigilance, divulging of information, content of prod-
uct information sheet and labels, and conduct of advertisers.2,4
Among its recommendations, the advertisements of prescribed
medications should include, at least, the following information:
generic name, commercial name, indication, dosage and presen-
tation, name of the excipients with known adverse drug reac-
tions, adverse drug reactions (ADR), precautions,
contraindications, warnings, main interactions, name and address
of the manufacturer or distributor and adequate references.2
We may remind that the requisitions of the WHO are recom-
mendations to associate countries and do not have the power
of law over the State, but Brazil, as a signing member, is ethi-
cally obliged to comply.
In Brazil, a previous regulation dealing with the advertise-
ment of medications lacked specificities and was flawed when
compared to other countries, as we can see in the Executive
Order 79,094 of January 5, 1977, which regulates the Act 6,360/
76, in its Article X, clause 118, II – ‘ that the text, figure, image
or projections do not insinuate false interpretations, error or
confusion regarding the composition of the product, its finali-
ties, mode of use or origin or claim non-proved therapeutical
properties at the time of its registration’, and clause 118, III –
‘contraindications, indications, precautions and warnings
about the use of the product shall be mandatorily declared’.
In 1978, ABIFARMA (Brazilian Association of Pharmaceu-
tical Industries), in 1978, established its ‘Voluntary Advertis-
ing Ethical Code’, aiming to guide the pharmaceutical indus-
try of Brazil in its ‘Best Practices for the Promotion and Com-
mercialization of Medications’.5 According to the report of
Herxheimer and Collier6 it is widely known how the self-regu-
lation is flawed, with no punishment for infringers.
Twenty years after the publication of the Act 6,360/76 and
its executive order, the Act 9,294/96 was published, but it was
only regulated by the competent agency four years later, by
means of ANVISA (Brazilian Sanitary Surveillance Agency),
which published in November 30, 2000 the Resolution 102 of
the Collegiate Board of Directors (RDC), approving the regu-
lation about advertisements.7
According to this regulation, the required information for
the promotion of prescription drugs are: commercial name
(when applicable), generic name, indication, posology,
contraindications, precautions and warnings (including inter-
actions and ADR). The information should be compatible with
the registration in the ANVISA (clause 13, I), besides the sci-
entific corroboration of the declared statements in the officially
recognized national and international literature (clause 15).7
Any advertisement has an important role in the choice of the
medication to be prescribed. Saporito & Goldberg8 state that
advertisement is the main source of rapid information to phy-
sicians as they use in average five minutes to obtain informa-
tion about medications they prescribe due to the overload of
work which reaches 50 to 60 weekly hours. Therefore, it is
evident the ethical dilemma in which are involved physicians
and pharmaceutics when choosing a medication in face of the
practice of advertisements.9
Regarding psychoactive medications, the advertisement in
medical specialties journals has a significant role in their divulg-
ing, as the advertisement of prescribed medications can only be
performed to prescribing and dispensing professionals.2,7
The assessment of advertisements of psychotropics is very
important, as they are the third most prescribed drugs.10 In a
recent study performed in the state of Minas Gerais, it was
observed that 27% of prescriptions of a great hospital were
composed by psychoactive medications.11 Besides, studies ac-
complished in the ‘70s and the ‘80s stated that the advertise-
ments of psychoactive medications tended to be less informa-
tive than those of other therapeutic classes.12,13 Up to now, no
study has assessed the influence of the country’s regulations
on the psychotropics in Brazil.
Therefore, knowing the quality of Brazil’s advertisements
of psychotropics and the impact of the regulatory acts in force
is fundamental to set up national policies about medications.14
Thus, this study tried to identify the influence of the adopted
Table 1- Regulations, date of publication and periods of data collection.
Regulations Month of publication Period of collection of addvertisements
Before After
U.S Export Act3 Dec./1986 Dec./85 to Nov./86 Jan./87 to Dec./ 87
WHO’s criteria2 May/1988 May/87 to April/ 88 June/88 to May/ 89
RDC* 102/2000 of ANVISA7 Nov./2000 Jan./00 to Dec./00 Jan./01 to Dec./01
*Resolution of the Collegiate Board of Directors.
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regulations and criteria for advertisement of psychoactive
medications in Brazilian psychiatric journals, and to assess
the content of these advertisements according to the thera-
peutical class.
Methods
Sample
Selection of sample periods
In order to verify the influence of regulations in the adver-
tisement of psychotropics we collected all published adver-
tisements before and after the implementation of each studied
regulation, obtaining thus six distinct periods (Table 1).
Selection of material sources
The survey of psychotropic advertisements was performed
in journals, after the establishment of the following criteria.
First, we established as an inclusion criterion advertisements
originated only from medical journals, as we needed to collect
advertisements since December 1985, what would be impos-
sible if we selected other sources of advertisement of manu-
facturers or materials of advertisers that had been divulged more
than fifteen years ago.
The second criterion was the choice of psychiatric jour-
nals, as these journals were those with more advertisements
of psychotropics.15
The third requisite was the inclusion of journals indexed
by the National Library of Medicine (List of Indexed Jour-
nals – in Index Medicus, 1999) and by LILACS (OPAS/OMS,
1997), which contained drug advertisements. Indexed jour-
nals have the advantage of an easy access to database que-
ries, being thus the most requested and known in several parts
of the country and more available at several university librar-
ies, besides assuring the regularity of the publications for data
collection purposes.
Brazilian journals which met established criteria were:
• Arquivos de Neuro-Psiquiatria (São Paulo)
• Revista de Psiquiatria Clínica (São Paulo).
• Jornal Brasileiro de Psiquiatria (Rio de Janeiro)
• Revista Brasileira de Psiquiatria (São Paulo) [former - Re-
vista ABP-APAL].
Collection, organization and identification of the
advertisements
In the 118 analyzed Brazilian issues there were 199 Brazilian
advertisements of 83 psychoactive medications, which, once
organized, were submitted to a detailed analysis of their content.
Analysis of content is defined as a technique to treat re-
search data focused on an objective, systematic and quanti-
tative description of the content of ‘communications’ (texts
and interviews, among others). Therefore, although having
originated in quantitative research, it seeks to interpret quali-
tative materials.16
We started the analysis skimming through the advertisements,
which is the first contact of the analyst with the studied mate-
rial, aiming to obtain ‘impressions and orientations’ about the
material,17 and guiding the development of the program for the
analysis of content.
Program for the analysis of the content of advertisements
We developed a program for the analysis of content of ad-
vertisements based on the requirements of the regulations for
the individual analysis of each advertisement. The program had
the following parts:
First part – Identification: it had the objective of identify-
ing which medication (commercial name, generic name, manu-
facturer and therapeutical class) and when (before or after the
respective publication of the regulation) the advertisement
was published.
Second part – Technical content: it aimed to identify and
quantify information about indication, dosage, posology, ADR,
interactions, precautions and warnings regarding: a) the pres-
ence; b) number of information per technical item; and c) em-
phasis each item received, given its print size.
Third part – General aspects: it encompasses aspects related
to figures and their characteristics, sentences of impact and
possible irregularities contained in the advertisements.
Data processing
Regarding data processing we developed an application,
generated in the language DELPHI, for critical data entry and
production of reports.
The application uses the information of the program to
analyze the content of the advertisement, in which all collected
Table 2 – Frequency of advertisements of psychoactive medications analyzed according to therapeutical class and type of prescription, according to
periods before and after the studied regulations.
Therapeutical Class and American Act WHO’s criteria RDC 102/2000 Total
special control list 22/12/1986 13/05/1988 30/11/2000
administrative rule 344/98 Before After Before After Before After N %
Antidepressants C 25 14 12 4 138 74 67 34.9
Anxiolytics B 47 38 22 32 28 28 195 25.5
Neuroleptics C 12 10 4 5 34 34 99 12.9
Hypnotics B 24 7 9 9 32 11 92 12.0
Anticonvulsants C 4 3 0 15 15 21 58 7.6
Antiparkinsonians C 8 0 0 3 5 0 16 2.1
Mood stabilizers C 1 1 2 0 4 0 8 1.0
Others 0 0 0 0 21 9 30 4.0
Total 121 73 49 68 277 177 765 100
Source: Revista Brasileira de Psiquiatria; Jornal Brasileiro de Psiquiatria; Revista de Psiquiatria Clínica and Arquivos de Neuropsiquiatria.
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advertisements were typed meeting the program’s pre-
established criteria.
Each advertisement was typed in a program composed by
six spreadsheets: one for identification, four for technical
analysis of content and one about the general aspects of the
advertisement.
The program displayed open spaces(allowing to type the
content of advertisements without limit of words), semi-open
spaces (allowing the typing only of numbers, such as the aver-
age number of words and print size) and closed spaces(allowing
to fill in only already-coded and pre-established information,
such as therapeutical class, type of notification, period to which
pertains the advertisement).
Data analysis
Advertisements were compared regarding the presence, av-
erage of information and print size per technical item before
and after each act.
Limitations of the study
We found the greatest difficulties regarding the analysis of
issues of the ‘80s, as not all of them were complete with all
their pages, what led us to more than one university library.
However, all published issues were analyzed. We also found it
difficult to analyze the technical content of the advertisements
due to the small sizes of their prints.
Results
General characteristics of the sample
The therapeutical classes with the highest frequency of adver-
tisements were the antidepressants, followed by anxiolytics and
neuroleptics, which together corresponded to 73.3% of Brazil-
ian advertisements (Table 2). Analyzed advertisements came
from 39 industries, being 15 of them Brazilian and 24 foreign.
The number of substances that were announced as having
antidepressant properties had the greatest increase in the last
years, what is explained by the appearance of the class of the
serotonin and noradrenalin inhibitors. The same occurred with
antipsychotic substances and the new atypical neuroleptics
which became the third most announced therapeutical class.
However, in the studied sample only 16% of announced medi-
cations are essential. According to the WHO’s program, essen-
tial medications are those deemed safe, efficient, with accept-
able quality and low price. Brazil’s Health Department, by means
of its executive order 3,916 of 1998, which established the Bra-
zilian policy of medications, also recommends the promotion
and the use of Brazil’s essential medications list (RENAME)
(Administrative rule 507/99), based on the WHO’s list.14
Influence of regulations on the content of advertisements
of psychoactive medications
Technical content of advertisements
 A – American act
In the studied period, there were only three products of Ameri-
can manufacturers that were advertised on Brazilian psychiat-
ric journals. None of them had neither information about drug
interactions nor the manufacturer’s address to allow the requi-
sition of information, both before and after the passing of the
American Act.
Even though we knew that the American act has not legal
power on Brazilian advertisements of non-American compa-
Table 3 – Presence of most frequent technical information according to the periods before and after the regulations on advertisements of psychoactive
medications.
Technical American Act dec/1986 WHO’s criteria May/1988 RDC 102/2000
Information Nov./2000
Before After Before After Before After
N (%) N (%) N (%) N (%) N (%) N (%)
Indications 37 (94.8) 31 (100.0) 18 (94.7) 19 (100.0) 57 (95.0) 33 (97.0)
Presentation 35 (89.7) 30 (96.7) 18 (94.7) 17 (89.5) 40 (66.6) 28 (82.3)
Posology 26 (66.6) 26 (83.8) 19 (100.0) 17 (89.5) 35 (58.3) 28 (82.3)
Generic name 34 (87.2) 29 (90.3) 17 (89.5) 18 (94.7) 51 (85.0) 34 (100.0)
Manufacturer 34 (87.0) 28 (90.0) 6 (31.7) 19 (100.0) 58 (96.5) 34 (100.0)
Total of addvertisements 39 (100.0) 31 (100.0) 19 (100.0) 19 (100.0) 60 (100.0) 34 (100.0)
Table 4 – Presence of least frequent technical information analyzed according to the periods before and after the regulations in advertisements of psychoactive
medications.
Technical American Act Dec/1986 WHO’s criteria May /1988 RDC 102/2000
Information Nov./2000
Antes Depois Antes Depois Antes Depois
N(%) N(%) N(%) N(%) N(%) N(%)
Adverse drug reations 20 (51.3) 20 (64.5) 10 (52.6) 10 (52.6) 22 (36.6) 25 (73.5)
Warnings 20 (51.3) 22 (70.9) 10 (52.6) 12 (63.2) 21 (35.0) 26 (76.3)
Interactions 20 (51.3) 21 (67.7) 9 (47.3) 11 (57.8) 22 (36.6) 25 (73.5)
Contraindications 20 (51.3) 20 (64.5) 10 (52.6) 12 (63.2) 22 (36.6) 25 (73.5)
References 6 (15.4) 7 (22.6) 8 (42.1) 9 (47.4) 33 (55.0) 20 (58.8)
Complying advertisements 4 (10.2) 5 (16.2) 6 (31.6) 5 (26.3) 8 (13.2) 13 (38.2)
Total of addvertisements 39 (100.0) 31 (100.0) 19 (100.0) 19 (100.0) 60 (100.0) 34 (100.0)
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nies, we chose to analyze all published advertisements in this
period, as there was a world-wide discussion about the quality
of prescribed drug advertisements. Besides, we decided to
maintain this global form to allow possible comparisons with
other regulations analyzed in this study.
In these periods, most frequent data found were indications,
posology, presentation, generic name and manufacturer’s name
(Table 3), whereas the least frequent were those that somehow
restricted the use such as ADR, interactions, warnings and
contraindications (Table 4).
Of note, the American act had no influence on Brazilian
advertisements, as expected (as before this act there were four
advertisements who presented all necessary technical informa-
tion and after its publication this number raised to five com-
plying advertisements (Table 4).
Regarding the content of information about possibly-quan-
tifiable technical items, we observed that the information
about ADR and drug interaction has increased (Table 5), al-
though still appearing at footnotes or in attached pages, in
small print.
B – WHO’s criteria
After the establishment of the WHO’s criteria there have been
few changes, except for the manufacturer’s name, which has
started to be present in all advertisements (Tables 3 and 4).
Table 5 shows that the content of technical information has
remained almost unchanged, except for two advertisements
which had more episodes of ADR after the establishment of
the WHO’s criteria. Of note, top extreme values remained un-
changed, except for one advertisement that had nine ADR af-
ter the publication of the WHO.
Regarding the emphasis given to technical items, the infor-
mation which facilitates the prescription of the medication (pre-
scription and posology) is presented in print sizes bigger than
that restricting the prescription (warnings, contraindications,
ADR and interactions).
C – RDC 102/2000
After 12 years of the WHO’s recommendations and after the
publication of the RDC 102/2000, information about indica-
tions, presentation and posology is still more frequent than that
about ADR, interactions, warnings and contraindications
(Tables 3 and 4).
The scientific basis that drug advertisements should present
is still hardly frequent, i.e., only slightly more than half (58.8%)
of advertisements analyzed after the publication of the RDC
had bibliographic references (Table 4). Of these, one third did
not belong to indexed journals or to officially recognized ref-
erences and two thirds belonged to scarcely representative
sources, such as manufacturer’s books and protocols, non-in-
dexed journals, bulletins of associations, non-published stud-
ies presented in meetings and oral presentations in seminars,
congresses or meetings of specialists.
The decrease of about 50% in the advertisements (60 adver-
tisements before and 34 after the implantation of the RDC -
Table 3), has coincided with an increase in the percentage of
all information, what could be explained by the fact that less
informative advertisements stopped being published. Anyway,
advertisements started to comply more with the proposals of
the resolution: 8 (before) and 13 (after) advertisements com-
plied - Table 4).
Regarding the content of ADR and drug interactions data, they
appeared more in the advertisements (Table 5). Despite the in-
crease in the content of these data, there is a growing distance
between the advertisement and the information page. The sum-
mary of the drug information sheet was rarely presented at the
advertisement’s footnote, and was mostly presented in pages
distant from the advertisement page, in hardly legible print that
ended not even being seen by the journal’s reader.
Data favoring the prescription, such as indications, posol-
ogy and presentation, were still being presented in print size
quite bigger than restricting ones such as ADR, interactions,
warnings and contraindications. We noted that the greater the
content of technical information the smaller the print size.
Irregularities present in the advertisements
We have considered as irregularities all information that the
regulations reported as forbidden and all and any statement
that was subjective or had not had officially recognized refer-
ences, according to the WHO and RDC 102/2000 criteria.
Some of these irregularities found in Brazilian advertise-
ments were:
Inadequate indications
‘It gives you back your tranquility and restores the equilib-
rium’; ‘equilibrium restored’, ‘single dose of tranquility’; ‘it
gives you back the natural way of life’; ‘tranquility with sim-
plicity’; ‘a light for your patients’.
Table 5 – Median of the Quantity of technical information of each technical item analyzed in Brazilian advertisements before and after the regulations in
advertisements of psychoactive medications.
Technical American act Dec./1986 WHO’s criteria RDC 102/2000
Information may /1988 Nov./2000
Before After Before After Before After
Md. (extr)** Md. (extr)** Md. (extr)** Md. (extr)** Md. (extr)** Md. (extr)**
Indications 2 (1-18) 2 (1-19) 1,5 (1-6) 1 (1-6) 1 (1-20) 2 (1-20)
Adverse drug reactions 4 (1-50) 7 (2-50) 3 (1-8) 6 (1-9) 13,5 (3-76) 16 (3-76)
Interactions 2 (1-7) 4 (1-9) 2 (1-9) 2 (1-9) 4,5 (1-18) 6 (1-20)
Warnings 5 (1-12) 5,5 (3-14) 6 (4-12) 7,5 (4-12) 8,5 (1-16) 9 (4-16)
Contraindications 2 (1-8) 2 (1-8) 2 (1-5) 2 (1-5) 2,5 (1-7) 3 (1-15)
Total of advertisements 39 31 19 19 60 34
*Md (extr) = median (extreme values)
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Approved/ reliable
‘You trust in it, you prescribe it’, ‘reliable for a higher num-
ber of patients’; ‘successful due to its use’, ‘The anxiolytic that
the medical community has approved’.
Standard or reference medication
‘Standard antidepressant’, ‘world leader in the treatment of
insomnia’; ‘WHO’s reference anxiolytic’; ‘first choice’ ‘high
efficacy standard’.
Approved by responsible agencies
‘Approved by the FDA and Brazil’s Health Department’.
Absence of interactions
‘Does not interact with other medications’; ‘does not inter-
act with alcohol’.
The most prescribed one
‘The most prescribed anxiolytic’, ‘for being the most pre-
scribed anxiolytic it needs to have something more’.
Quick answer
‘Rapid beginning of action’; ‘rapidness with lower sedation’;
‘rapidness and efficacy in depression, panic and OCD’; ‘im-
mediate relief’.
Suggestion of a wide spectrum
‘An anxiolytic which meets all needs’; ‘great range of ac-
tion’; ‘wide solution’; ‘efficient in all forms of depression’,
‘Wherever anxiety might hide or is manifested’.
Physiological action
‘The right physiological sleeping’; ‘the most physiological
of inductors’.
Certainty of efficacy
‘Certainty of efficacy’.
Pharmacokinetics
‘Superior pharmacokinetics for a better life’.
After the publication of each regulation we noted a decrease
in the number of irregularities, although none of the regula-
tions was enough to terminate them (Table 6).
Discussion
General aspects of classified advertisements
In the ‘80s (before and after the American act and the WHO’s
criteria), the most prevalent advertisements were those of
anxiolytic and hypnotic medications while from 2000 to 2001
advertisements of antidepressant prevailed. Similar data were
observed in one study, in which advertisements of psychotro-
pics in medical journals in Nordic countries had been analyzed
for 20 years. This study named the advertisements from years
1975 to 1985 as the ‘Age of sleeping pills’ and those from the
middle of the ‘90s onwards as the ‘Age of antidepressants’.18
We found that the promotion of psychoactive medications
by pharmaceutical industries is similar in several countries,
regardless their epidemiological situations. In Brazil, for ex-
ample, the prevalence of psychiatric disorders does not exceed
10.2%.19 Of note, thus, the lack of engagement of manufactur-
ers in the demands of the country in which the product is com-
mercialized, i.e., it is as if the need of a medication came be-
fore the epidemiological need.
Or else, advertisements could have been favoring a higher
number of diagnoses and treatments of certain diseases, there-
fore altering the epidemiological profile of the region in which
the medication is available. It is believed that this phenom-
enon could have occurred in the ‘80s with anxiolytic and hyp-
notic medications and more recently with antidepressants, as
the latter have been submitted to a wider and less adequate
utilization in all senses, reaching nearly to the idea of a psychi-
atric panacea.20
Influence of regulations on the advertisements of
psychoactive medications
The American act (1986) was not sufficient to improve the
quality of advertisements. It is believed that the indifference
regarding this act might have occurred due to the lack of con-
trol of the Brazilian government and to the lack of examina-
Table 6 – Frequency of irregularities found in the advertisements of psychoactive medications before and after the studied regulations.
Total Export Act 99,660 WHO’s criteria RDC 102/2000
Dec./1986 May/1988 Nov./2000
Before After Before After Before After
(13 months) (12 months) (6 months) (12 months) (13 months) (12 months)
Subjective indications 26 10 5 4 5 2 0
Approved/Confidence 15 1 1 0 0 7 6
Reference / Standard 12 1 2 0 0 4 5
Approved by FDA/ MS/ APA 11 0 0 0 0 7 4
Without interaction with other drugs 6 2 1 1 2 0 0
The most prescribed one 5 0 0 0 0 3 2
Quick response 5 2 3 0 0 0 0
Wide spectrum 4 1 0 1 0 1 1
Physiological action 4 1 0 1 1 1 0
Certainty of efficacy 2 0 0 1 1 0 0
Pharmacokinetics 1 0 0 0 0 1 0
Irregular advertisements/
Total of advertisements 12/39 8/31 6/16 7/19 19/60 12/34
Rev Bras Psiquiatr 2003;25(3):146-55
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tion by the headquarters of American companies of the promo-
tional materials divulged in Brazil.
There have not been great changes in the content of adver-
tisements published in psychiatric journals after the publica-
tion of the WHO’s criteria (1988). This lack of adherence to
the regulation might be explained by the criteria being only
recommendations to associated countries and not having the
power of law. However, Brazil, as a signing member, was
obliged to comply and to enforce the regulation. The non com-
pliance with the WHO’s criteria might have occurred due to a
flaw in their divulging or still due to the omission of Brazilian
sanitary agencies.
The publication of the RDC 102/2000 reinforced the same
requirements that had been already established 12 years before
by the WHO’s criteria (1988). However, we observed that the
Brazilian regulation had an impact on the advertisements of
psychoactive medications, as it regulation halved the number
of advertisements published in the psychiatric journals (the 60
advertisements published before the RDC were reduced to 34
after it – Table 3), and half of Brazilian manufacturers can-
celed their circulating advertisements.
Actually, the impact of the RDC was not necessarily related to
the improvement in the quality of advertisements, as only 38.2%
of them complied with the regulation after its publication, but to
the cancellation of less complete advertisements. This fact is
evident when analyzing the items that restrict the prescription
(ADR, interactions, warnings and contraindications); therefore,
before the RDC only 22 out of 60 advertisements (35%) had
these items; after the RDC the number of advertisements de-
creased to 34, of which 25 had these items (73.5%).
Nevertheless, the regulation is thought to have had a positive
impact. It is believed that out of the three studied regulations,
only the RDC had a positive impact on the advertisements, per-
haps because it is a Brazilian regulation and therefore more eas-
ily divulged and controlled in the country than the others.
Summing up: regardless the studied period, the most fre-
quent and most highlighted data due to their print size were
the ones that favored the prescription: indications, posology
and presentation, whereas the less frequent and less impor-
tant information were those restricting the prescription of the
medication such as ADR, drug interactions, contraindications
and warnings.
Similar finding were also observed in other promotional
sources. Pizzol et al21 who analyzed pieces of medication ad-
vertisement distributed to physicians in two cities of the state
of Rio Grande do Sul observed that 73% of them presented the
posology in larger print sizes than those of general precautions
which were present in only 43% of the collected material.
The same occurs in other countries; in Russia, less than 10%
of advertisements contain precautions, contraindications and
drug interactions and 2% had bibliographic references.22 In
Argentina, 100% of the material of advertisers had no infor-
mation about drug interactions, contraindications, ADR and
precautions; 46% of the references were incorrect and we could
not find them; and 69% of them were difficult to access as they
were from other countries.23
We might speculate, thus, that in promotional materials which
are divulged by other mass media, the flaws in the information
are still higher than those found in indexed journals.
Although the bibliographic references have increased their
frequencies in advertisements along the years, less than 60%
of advertisements published in 2001 had them and one third
had non-indexed references. The fact that medication adver-
tisements lack informative and scientific character is consid-
ered a severe irregularity, according to the criteria of several
regulatory agencies.24-26
Irregularities
The most frequent irregularities were related to subjective
indications. After the publication of the three regulatory acts,
35.3% of the advertisements still had some irregularity.
Subjective indications reinforce erroneous concepts and
prejudices of society. Carlini10,13 found that, in Brazil, women
were overrepresented in advertisements of psychoactive medi-
cations, and generally had diffuse and apparently unmotivated
illnesses; on the other hand, when the figure was a man, indi-
cations for the use of the medication were due to tension, ex-
cess of responsibility or of work.
The stereotyped image of emotive, irrational and complain-
ing women, presented in anxiolytic advertisements, leads to
overmedication, to the so-called ‘housewife syndrome’, mainly
for ‘nervous conditions’ and ‘insomnia’, making them receive
60% more of any medication, with a greater difference for the
cases of anxiety, depression, tension and insomnia.27
Women figures were much more common in the advertise-
ments of anxiolytics, being the male/female ratio 1:2, the same
found by Noto et al28 who analyzed the prescriptions of benzo-
diazepines in two cities of the state of São Paulo. The authors
found that women were prescribed twice anxiolytics than men.
The irrational appeal of advertisements is reflected in the medi-
cal prescription, leading to a bias between mental disorders
and gender.29
Besides female figures, the use of metaphors is not rare, i.e.,
symbols which perform a direct association with the product:
owls, rainbows, dolls, animated pills, butterflies, etc. Lion,30
when presenting advertisements of medications to physicians
without giving their names, observed that those which con-
tained metaphors were more recognized than the others.
Anyway, the use of benzodiazepines is high in the Brazilian
population. According to a survey in the state of Rio Grande
do Sul, the prevalence of use of benzodiazepines is 46.7%,31
i.e., almost half of the population have already used at least
once in their lifetime this therapeutical class.
On the other hand, advertisements of neuroleptic medica-
tions used much more male figures (6:1), usually adult and
aged men. In this case it is suggested that aged men were
stereotyped as having psychotic disorders. The same was ob-
served by Riska & Huggund,32 when analyzing the advertise-
ments of neuroleptic medications in medical journals of Nor-
dic countries.
Schizophrenia and other psychoses are much less common
among elderly people; however, in the U.S. 750,000 people
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aged above 65 receive antypsychotic drugs, and the estimated
prevalence of schizophrenia among the elderly for whom there
would be the need of using neuroleptics is near to 92,000
people.33 Besides, the advertisements of neuroleptics deal with
the product’s confidence and security mentioning its time in
the market and mainly the millions of patients who had al-
ready used the medication.24 We observed that the process of
medicalization and stereotyped representation of mental disor-
ders in drug advertisements occurs all over the world.
The advertisements of psychotropics even use a scientific
language but their messages tend to have a marketing language,
presenting messages of autonomy, satisfaction and plenitude.34
Deceitful messages were observed in advertisements of an-
tidepressants suggesting a rapid effect for the treatment of panic
disorder, from two to three weeks. Studies claim that the start
of response to the antidepressive treatment occurs, at least, af-
ter 15 days. In the treatment of panic disorders, the effects ap-
pear after two to eight weeks and the beginning of withdrawal
of the medication, after six months to one year of treatment.
For obsessive-compulsive disorder (OCD) 12 to 26 weeks of
medication are recommended.35
A launching advertisement of a hypnotic medication claimed
that one out of two people had already had difficulties to sleep
and informed that an innovatory medication would be soon
reaching the market. Indeed, the incidence of complaints about
insomnia is high in the population.36 However, insomnia can
stem many times from other comorbities, such as psychiatric
disorders and respiratory problems, situations in which the use
of hypnotics should be avoided. Besides, simple measures,
called as ‘sleep hygiene’ should be adopted: avoiding caffeine
and naps after the meals and the performing of regular physi-
cal activities can help the therapy of insomnia, making unnec-
essary the use of hypnotics.37
Mood stabilizers, medications for the treatment of the syn-
drome of alcohol and tobacco abstinence and the acetylcho-
linesterase inhibitors, besides some antidepressants launched
in the market, did not contain any technical information, being
those the classes which disagree more with the studied regula-
tory acts.
The irregularities most commonly found by the agencies re-
sponsible for the assessment of medication advertisements and
in studies assessing the already-published promotional materi-
als,23,26,38-43 were:
• Purposeless scientific studies;
• Non-published references;
• Difficult access to the quoted scientific articles;
• Incorrect statistical package;
• Incorrect methodologies;
• Results bias;
• Non-proved experimental data;
• Omission of unfavorable reports;
• Omission of failure rates;
• Failure to inform the consequences of use;
• Selection of some precautions and warnings and omission
of some data from the original drug labeling;
• Presence of unnecessary information such as FDA approval;
• Suggestion of incorrect doses regarding the mentioned
clinical study;
• Dangerous conclusions, extrapolations and percentual
projections in a small sample;
• Vaguely-described qualifications of safeness, effectiveness
and superiority (one of the most observed in this study);
• Brief’s summary’s drug labeling and advertisement
displayed in different pages.
Jaillon (2000)26 reports that out of 9,000 advertisements that
are annually registered by French manufacturers, only in 1% of
them there is no need of further change before the divulging.
Despite the advance in the regulations, such as the RDC 102/
2000, published by ANVISA in Brazil, we do not have yet a
system for the analysis of medication advertisements as the
FDA and the French agency. A possible consequence of this
failure is expressed in one study performed in the ‘80s which,
when analyzing advertisements of prescribed medications in
Brazil, had reported that the advertised material had used flawed
statistics and methodology, ‘scientific studies’ with biased
samples, lack of a control group, small experimental groups
and non-statistically significant diferences.44
It would be interesting to perform further studies, twenty years
after Victora’s data44, in order to verify the current situation,
adding to these data the quality of bibliographic references,
what could not be performed in our study.
The implantation of any of the regulations did not suffice to
prevent the irregularities in medication advertisements. Up to
day old irregularities are still occurring and new ones have
appeared. Actually, what has happened was an increase in the
types of irregularities.
Conclusions
1. Assessing the influence of the three studied regulations –
the American act (‘Export act’), WHO’s criteria and the
RDC 102/2000-, we concluded that the only one that
promoted some impact on medication advertisements was
the RDC 102/2000. Actually, the number of inadequate
published articles decreased by fifty percent. However, this
regulation, as the others, was not enough to enhance the
quality of the technical content of the remaining
advertisements, as less than half (38.2%) of them had all
requested technical information and 35.5% still had at least
one irregularity;
2. Despite the advances in the regulations with the publication
of the RDC 102/2000, the same flaws and the mode of
arranging the information which were already present since
the first years of the study (1986) were still present. That
is, the information which favors the prescription (such as
indications, presentations and posology) is the most frequent
and is still presented in print size greater than that which
restricts it (such as ADR, medication interactions,
contraindications, precautions and warnings);
3. In the year which preceded the publication of the RDC 102/
2000, 55% of advertisements had bibliographic references
and after its publication they have not exceeded 58.8%.
However one third of them were references of protocols
Rev Bras Psiquiatr 2003;25(3):146-55
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and materials from the manufacturer itself, non-indexed
journals, bulletins of associations, and not-published
congress presentations. This suggests that further studies
are needed to assess the methodological quality and the
content of the references cited in the drug advertisements;
4. We observed inadequate advertisements such as: suggestion
of start of effects in advertisements of antidepressants;
suggestion of pharmacist treatment for all types of insomnia
in an advertisement of a hypnotic; omission of information
regarding the maximum treatment period in all
advertisements of anxiolytics and the omission of mandatory
warnings in advertisements of neuroleptics. These failures
are deemed irregularities, according to the clauses 4 and 13
of the RDC 102/2000;
5. There are still inadequate and subjective indications for
psychoactive medications, such as, ‘it solves the problems
without creating others’, or ‘the antidepressant which brings
life back in its best expression’ hinting a solution for the
daily problems, what has been observed since the ‘70s and
may generate an overmedicalization for diffuse and
emotional illnesses;
6. Female figures are more frequent in advertisements of
benzodiazepines and antidepressants; on the other hand,
male figures are more frequent in advertisements of
neuroleptics, favoring a stereotype between gender and
psychiatric disorders, suggesting that anxiety and depression
are female and young symptomatologies, whereas
schizophrenia and other psychoses are male and elderly
symptomatologies, therefore indirectly influencing the
medical conduct;
7. Data suggest that most of pharmaceutical industries do not
have a commitment with the Brazilian policy of medications
regarding the priority to promote essential psychoactive
medications, as less than 16% of the advertisements were
of medications with this classification;
8. Our findings suggest that other measures are needed besides
the regulations, such as educational programs promoted by
ANVISA directly for pharmaceutical manufacturers and
health professionals. A direct line with associations such
as the ABP (Brazilian Psychiatric Association) should be
also created, and these associations, after an adequate
analysis of the advertisements, would file denounces to
ANVISA against inadequate advertisements;
9. Journals of medical specialties should reassess their conduct
regarding advertisements. For example, not allowing the
publication of the brief summary’s drug labeling in illegible
print size or else that this summary and the advertisement
be in different pages and distant from the advertisement.
10. The implantation of disciplines in the program content of
Medical and Pharmacist schools enabling these
professional to perform a critical analysis of the material
of drug promotion or the possibility of performing
specialization courses to already-graduated physicians and
pharmacists with the same finality. This discipline or
course should aim to train professionals for the critical
and methodological analysis of scientific studies
(perception of sample errors, of the extrapolation of in
vitro data as if they were in vivo ones or experimental as
if they were clinical ones, analysis of the adequacy of
statistical packages) and to warn them against the possible
stereotypes of medication advertisements comparing them
with epidemiological data.
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